Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
Netherlands
Amsterdam University Medical Center, Amsterdam Maastricht University Medical Center, Maastricht St. Antonius Ziekenhuis, Nieuwegein Erasmus University Medical Center, Rotterdam Age range
18 Years and older
Last updated February 2026